MetLife Investment Advisors LLC Acquires New Position in Eidos Therapeutics Inc (NASDAQ:EIDX)

MetLife Investment Advisors LLC acquired a new position in Eidos Therapeutics Inc (NASDAQ:EIDX) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 8,453 shares of the company’s stock, valued at approximately $198,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EIDX. BlackRock Inc. raised its stake in shares of Eidos Therapeutics by 57.9% during the fourth quarter. BlackRock Inc. now owns 1,149,364 shares of the company’s stock valued at $15,814,000 after acquiring an additional 421,666 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Eidos Therapeutics by 193.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 425,000 shares of the company’s stock worth $9,967,000 after buying an additional 280,000 shares in the last quarter. Victory Capital Management Inc. bought a new position in Eidos Therapeutics in the fourth quarter worth approximately $2,835,000. Hillhouse Capital Advisors Ltd. bought a new position in Eidos Therapeutics in the fourth quarter worth approximately $2,458,000. Finally, Vanguard Group Inc. raised its stake in Eidos Therapeutics by 297.3% in the third quarter. Vanguard Group Inc. now owns 198,673 shares of the company’s stock worth $1,983,000 after buying an additional 148,673 shares in the last quarter. 34.01% of the stock is owned by institutional investors and hedge funds.

In related news, insider Jonathan C. Fox sold 15,000 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $40.04, for a total transaction of $600,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan C. Fox sold 5,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $25.46, for a total transaction of $127,300.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,000 shares of company stock valued at $2,305,940.

NASDAQ:EIDX traded down $2.81 during mid-day trading on Thursday, hitting $36.33. The company’s stock had a trading volume of 254,405 shares, compared to its average volume of 145,300. The business’s fifty day moving average price is $32.70. The company has a market capitalization of $1.44 billion and a PE ratio of -19.53. Eidos Therapeutics Inc has a 1 year low of $8.89 and a 1 year high of $41.35. The company has a current ratio of 19.04, a quick ratio of 19.04 and a debt-to-equity ratio of 0.01.

Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32). On average, equities research analysts predict that Eidos Therapeutics Inc will post -1.73 EPS for the current fiscal year.

EIDX has been the subject of a number of recent research reports. BMO Capital Markets downgraded shares of Capital Power from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 8th. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Finally, BTIG Research set a $14.00 price objective on shares of ARBOR RLTY TR I/SH and gave the company a “buy” rating in a report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $30.00.

Eidos Therapeutics Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Featured Story: Growth Stocks

Institutional Ownership by Quarter for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.